BC-LI-0186
(Synonyms: 4-(4-异丙基-2,3-二甲基-5-氧代-2,5-二氢-1H-吡唑-1-基)-N-(2-苯氧基乙基)苯磺酰胺) 目录号 : GC50572
一键复制产品信息
BC-LI-0186是一种有效、高选择性的亮氨酰-tRNA合成酶（LRS）与Ras相关GTP结合蛋白D（RagD）相互作用的抑制剂，IC50值为46.11nM。
Cas No.:695207-56-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BC-LI-0186 is a potent and highly selective inhibitor of the interaction between leucyl-tRNA synthetase (LRS) and Ras-related GTP-binding protein D (RagD), with an IC₅₀ value of 46.11nM[1-2]. By competitively binding to the RagD interaction site on the LRS protein, BC-LI-0186 specifically disrupts the LRS – RagD interaction and induces apoptosis in cancer cells. BC-LI-0186 is primarily used in cancer‑related research[3-4].
In vitro, treatment of SW620 colon cancer cells with BC-LI-0186 (0.1–20μM) for 24 hours. BC-LI-0186 significantly inhibited leucine‑induced S6K phosphorylation and blocked the interaction between LRS and RagD, thereby suppressing mTORC1 signaling activation and ultimately inducing cancer cell apoptosis[1]. In C2C12 myoblasts, treatment with BC-LI-0186 (4μM) for 72 hours. BC-LI-0186 disrupted LRS – RagD binding, relieved mTORC1‑mediated suppression of the IRS1‑PI3K‑Akt pathway, and significantly promoted myogenic differentiation[5].
In vivo, in an LSL K‑ras G12D mouse lung cancer model, BC-LI-0186 (20mg/kg; intraperitoneal injection; 5 days per week for 2 weeks) significantly reduced tumor volume, increased expression of activated caspase‑3 in tumor tissue, and inhibited phosphorylation of the mTORC1 signaling markers pS6 and pAKT[6]. In a BALB/c nude mouse H460 cell xenograft model, BC-LI-0186 (20mg/kg; i.p.; 5 days per week for 2 weeks) combined with trametinib (1mg/kg; oral; 5 days per week) synergistically suppressed tumor growth, decreased the tumor volume increase rate, enhanced activated caspase‑3 expression in tumor tissue, and inhibited pMEK and pS6 signaling pathway activation without causing significant body weight changes[7].
References:
[1] Kim JH, Lee C, Lee M, et al. Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction. Nat Commun. 2017 Sep 29;8(1):732.
[2] Choi H, Son JB, Kang J, et al. Leucine-induced localization of Leucyl-tRNA synthetase in lysosome membrane. Biochem Biophys Res Commun. 2017 Nov 18;493(2):1129-1135.
[3] Kim JH, Jung K, Lee C, et al. Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction. Bioorg Chem. 2021 Jul;112:104907.
[4] You JS, Karaman K, Reyes-Ordoñez A, et al. Leucyl-tRNA Synthetase Contributes to Muscle Weakness through Mammalian Target of Rapamycin Complex 1 Activation and Autophagy Suppression in a Mouse Model of Duchenne Muscular Dystrophy. Am J Pathol. 2024 Aug;194(8):1571-1580.
[5] Son K, You JS, Yoon MS, et al. Nontranslational function of leucyl-tRNA synthetase regulates myogenic differentiation and skeletal muscle regeneration. J Clin Invest. 2019 Apr 15;129(5):2088-2093.
[6] Kim EY, Lee JG, Lee JM, et al. Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer. Ther Adv Med Oncol. 2019 May 19;11:1758835919846798.
[7] Lee SH, Kim EY, Han JM, et al. Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non-Small Cell Lung Cancer. Cancer Res Treat. 2023 Jul;55(3):851-864.
BC-LI-0186是一种有效、高选择性的亮氨酰-tRNA合成酶（LRS）与Ras相关GTP结合蛋白D（RagD）相互作用的抑制剂，IC50值为46.11nM[1-2]。BC-LI-0186通过竞争性地与LRS蛋白上与RagD相互作用的位点结合，从而特异性破坏LRS-RagD的相互作用，引起癌细胞凋亡。BC-LI-0186主要用于癌症相关的研究[3-4]。
在体外，BC-LI-0186（0.1-20μM）处理SW620结肠癌细胞24小时，BC-LI-0186可显著抑制亮氨酸诱导的S6K磷酸化，并阻断LRS与RagD的相互作用，从而抑制mTORC1信号通路激活，最终诱导癌细胞凋亡[1]。BC-LI-0186（4μM）处理C2C12成肌细胞72h，BC-LI-0186通过破坏LRS-RagD结合，解除mTORC1对IRS1-PI3K-Akt通路的抑制，显著促进成肌分化[5]。
在体内，在LSL K-ras G12D小鼠肺癌模型中，BC-LI-0186（20mg/kg；腹腔注射；每周5天持续2周）显著降低肿瘤体积，并诱导肿瘤组织中活化caspase-3表达增加，同时抑制mTORC1信号标志pS6和pAKT的磷酸化水平[6]。在BALB/c裸鼠H460细胞异种移植模型中，BC-LI-0186（20mg/kg；腹腔注射；每周5天持续2周）联合曲美替尼（1mg/kg；口服；每周5天）显著协同抑制肿瘤生长，降低肿瘤体积增加率，并增强肿瘤组织中活化caspase-3表达，同时抑制pMEK和pS6信号通路激活，且未引起显著体重变化[7]。
| Cell experiment [1]: | |
Cell lines | SW620 cells (human colon cancer cell line) |
Preparation Method | SW620 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with BC-LI-0186 at concentrations ranging from 0.1 to 20μM for 24 hours. |
Reaction Conditions | 0.1-20µM; 24h. |
Applications | BC-LI-0186 selectively inhibited leucine-dependent mTORC1 signaling by disrupting the LRS-RagD interaction, leading to dose-dependent suppression of S6K phosphorylation (IC₅₀=81.4nM). BC-LI-0186 induced apoptosis via cleavage of PARP and caspase-3, with an EC₅₀ of 62nM for cell death. The compound also blocked lysosomal localization of LRS and Raptor, suppressing mTORC1 activation without affecting LRS catalytic activity. |
| Animal experiment [2]: | |
Animal models | LSL K-ras G12D mice (lung cancer model) |
Preparation Method | Mice were intraperitoneally administered BC-LI-0186 (20mg/kg, twice daily) for 5 days per week over 2 weeks. Tumor progression was monitored via microcomputed tomography (μCT) before and after treatment. Lung tissues were harvested for histopathological and immunohistochemical analysis post-treatment. |
Dosage form | 20mg/kg; i.p.; twice daily for 2 weeks. |
Applications | BC-LI-0186 significantly suppressed tumor growth by approximately 40%, comparable to cisplatin. BC-LI-0186 induced apoptosis via increased activated caspase-3 expression in tumor tissues and inhibited mTORC1 signaling, evidenced by reduced phosphorylation of S6 and AKT. |
References: | |
| Cas No. | 695207-56-8 | SDF | |
| 别名 | 4-(4-异丙基-2,3-二甲基-5-氧代-2,5-二氢-1H-吡唑-1-基)-N-(2-苯氧基乙基)苯磺酰胺 | ||
| Canonical SMILES | CC(C1=C(N(N(C2=CC=C(S(=O)(NCCOC3=CC=CC=C3)=O)C=C2)C1=O)C)C)C | ||
| 分子式 | C22H27N3O4S | 分子量 | 429.54 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3281 mL | 11.6404 mL | 23.2807 mL |
| 5 mM | 465.6 μL | 2.3281 mL | 4.6561 mL |
| 10 mM | 232.8 μL | 1.164 mL | 2.3281 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet